Concerns about the escalating global spread of COVID-19 panicked the markets big time at the close of the month. With investors rushing to the sidelines, it only took five days for the Dow Jones Industrial Average to drop more than 10% from its all-time high, getting close to the 30,000 mark. Read More
Abpro Therapeutics Inc. has granted an exclusive license to Abpro Bio Co. Ltd., the former Ugint Co. Ltd., to develop and commercialize two bispecific antibodies in Asian markets, including greater China, Japan and South Korea. Read More
With battles over the future of American health care being waged in the courts and at the ballot box, JAMA, the Journal of the American Medical Association, has devoted its latest issue to better understanding what Deputy Editor Gregory Curfman called the "challenging problem" of "relentless increases" in prescription drug prices. Read More
Sadly, a major part of the answer to why drugs are so expensive appears to be “because they can be.” But the high cost of drugs has also spurred a number of attempts to find medicines that are innovative but remain affordable. Drug repurposing, or using a drug that has been developed for one ailment to treat a different one, is one such strategy. Read More
Strongly favorable six-month data disclosed on Jan. 9 by Applied Genetic Technologies Corp. (AGTC) from its ongoing phase I/II program with an adeno-associated virus (AAV) gene therapy for X-linked retinitis pigmentosa (XLRP) did more than provide a whopping stock boost. Read More
Against the backdrop of the global spread of COVID-19, India announced restrictions Tuesday on the export of 26 active pharmaceutical ingredients (APIs) and formulations of those ingredients. Read More
HONG KONG – MBD Co. Ltd. and Azothbio Inc., both based in South Korea, have entered an agreement for rare cancer drug development using an AI-powered drug discovery platform. Read More
PERTH, Australia – With the Brexit split now official, Australia’s Therapeutic Goods Administration is trying to figure out the impact to its life sciences industry and the new trade relationships that will take effect after the transition period ends. Read More
New hires and promotions in the biopharma industry, including: AB2, Addex, Applied Therapeutics, Bluerock, Oculis, Rafael, Sumitomo Dainippon, Sutura. Read More
Biopharmas raising money in public or private financings, including: Akouos, Emmaus Life Sciences, Lipidio Pharmaceuticals, Pliant Therapeutics, Xortx Therapeutics. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arrowhead, Avita, Bioarctic, CNS, Eisai, Mina, PDC*Line, Neuraly, Prevail, Puretech, Targovax, VBI. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Ayala, Epicentrx, Genentech, Immunomic, Kempharm, Kura, Novartis, Stealth. Read More
